常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.06/-0.66
|
|
企业价值
44.80M
|
| 资产负债 |
|
每股账面净值
0.48
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
11.98M
|
|
每股收益
0.92
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/16 13:34 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413. |

1.65 
